The entry by GE into the core lab business via its acquisition of Abbott's clinical diagnostics businesses follows a similar move by Siemens last year, and suggests IVD may be best suited for generalist industrial giants. While the pricing pressures that have dogged this segment of diagnostics are not likely to abate, existing players--including Abbott--are continuing to develop high-margin molecular diagnostic tests that they expect the new players will want to incorporate into their platforms.
Mark L. Ratner
In January, the GE Healthcare division of General Electric Co. announced its intention to buy Abbott Laboratories Inc. ’s core lab diagnostics business for $8.13 billion. [See Deal] For...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
